[請益] 台微體(4152)的吸入式HCQ新冠肺炎解藥?
A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study
原文連結:
https://www.biorxiv.org/content/10.1101/2020.07.09.196618v1.full
報告介紹如下,全文請見連結
INTRODUCTION
Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, is inexpensive, safe, and well tolerated by most patient populations, including those with chronic diseases or immunocompromised status. HCQ is a weak diprotic base that can pass through the lipid cell membrane and preferentially concentrate in acidic cytoplasmic vesicles. HCQ is being studied to prevent and treat coronavirus disease 2019 (COVID-19), possibly via blocking the interactions between virus and angiotensin-converting
enzyme-2 (ACE-2) receptor as well as sialic acids receptor and has shown potential in vitro (1, 2) and preliminary clinical results (3, 4). As of Jul 8, 2020, a total of 232 studies involves HCQ use among 2478 clinical trials for COVID-19 registered with the clinicaltrials.gov.
However, the effective in vivo levels as well as the optimal dosing regimen of HCQ for treating COVID-19 remains unclear. The in vitro EC50 values (0.72 to 17.31 M) proposed for optimized dosing regimens are based on extracellular drug concentration (1, 2). A higher lung (intracellular) concentration to predict the in vivo antiviral efficacy was suggested (5). The HCQ concentration (6.7 g/mL) required to clear 100% of SARS-CoV-2 in vitro might not be achievable with the currently proposed oral
dosing regimen of 800 mg HCQ sulfate orally daily, followed by a maintenance dose of 400 mg given daily for 4 days (2, 6). Further, a high cumulative doses of HCQ may raise concerns of systemic toxicity, including cardiotoxicity (7).
An alternative strategy is needed to bridge the gap between in vitro and clinical use of a potentially effective agent in the context of COVID-19 pandemic. A drug delivery directly to the respiratory tracts while minimizing the systemic exposure is a desirable alternative (5). In this report, a proof-of-concept study was conducted to evaluate the systemic pharmacokinetics (PK) profiles and tissue distribution following a single dose of inhalable liposomal HCQ in a rat model and compared to that of
unformulated HCQ through intravenous (IV) delivery.
看起來是有新的HCQ相關吸入式的新冠肺炎治療方案,似乎可以降低一般服用的副作用,而且有進行了動物試驗,未來不知有沒有機會也得到BARDA贊助。而文中也有提到這項新藥的廠商是Taiwan Liposome Company,也就是台灣的台微體公司(4152),去看籌碼發現有在公司附近的分點囤了蠻多的貨,覺得事有蹊俏,不知可不可以提前佈局,等待中文新聞出來應該可以拉一波。想請教生技醫療專業的人怎麼解讀這份報告,感謝!!!
-----
Sent from JPTT on my iPhone
--
樓下allin 了
硬啦硬啦
噴了 是往下
想出脫啊
remain unclear
吸入性的奎寧 也不過是奎寧啊=.=
股價能不能衝,要問投資人解讀而非專業解讀 XD
機制有可能,但不做不知道,但這個至少要從一期開始
用低劑量奎寧直接作用在發炎最嚴重的肺?
但持續吸入的話 順著肺靜脈回到心臟的副作用要注意?
奎寧的作用機制都不明了 不要期待用吸的會多有效
什麽都要扯上新冠,好像已沒人說X漢了
太猛 心臟濃度也很低 肺卻能持續作用
噴噴 往下噴
吸大痲比較實用
都在騙不懂的..
40
Re: [問卦] 伊維菌素是怎麼突然被討論的大家好,我是肥宅 分享一下有關伊維菌素的五四三。 事實上,不是有人突然想試狗藥, 而是當時肺炎傳染開來的極度恐慌當下, 很自然的,36
[其他] 小型雙盲實驗顯示, 羥氯喹對武漢肺炎有效出處: 標題: Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial36
[標的] COVID-19 台灣藥物進度整理------------------------------------------------------------------------- 1.發文前請先詳閱[標的]分類發文規範,未依規範發文將受處份。 2.發標的文未充實內文,多空理由不充實者,板規1-1-5或4-4處份 3.進退場機制若非長期投資,請輸入停損價,否則依板規1-1-6處份 4.若為長期投資,但無充份分析理由,將依板規1-1-5處份20
Fw: [整理] 閻麗夢博士: HCQ 不是神藥, 但是能救命!作者: saveme (hihi不要在底下推噓文, ) 看板: nCoV2019 標題: [整理] 閻麗夢博士: HCQ 不是神藥, 但是能救命! 時間: Mon Aug 3 01:59:41 2020 發稿單位:班農戰爭室 (War Room) 發稿時間:7/3038
[爆卦] 鯊魚可以提煉對抗COVID用的特殊蛋白正式論文: 大意與原理: 研究人員表示,他們發現鯊魚特有的一種蛋白質能夠中和 COVID-19 病毒及其變種。“這些微型的抗體蛋白可以進入人類抗體無法進入的角落和縫隙。15
[爆卦] 免驚!伊維菌素等藥對肺炎藥物動力學來惹大家好,我是為大家分享曙光與希望的肥宅 今天要以猥褻版本來說明伊維菌素、瑞德希韋、HCQ(羥奎寧)的藥物動力學 研究報告來源: -17
Re: [新聞] 健亞紅斑性狼瘡新藥有望成奎寧2.0 估抱歉我是來吐槽的 ※ 引述《tonyparker18 (tonyparker183)》之銘言: : 健亞紅斑性狼瘡新藥有望成奎寧2.0 估明年完成臨床試驗 : 1.原文連結: :12
Re: [爆卦] 今天有反疫苗遊行推文討論到 伊維菌素 討論一下 其實論文 meta-analysis 是說到有效的 可以去看看論文分析 在一篇印度疫情分析中可以看到 印度中一省 Kerala 不用依維箘素疫情大爆發 的消息5
[其他] 台微體開發中的吸入懸浮劑具有成台微體科學報告顯示 極低劑量的微脂體羥氯喹寧吸入劑型可降低心毒性並提高肺暴露量 可望成為新冠肺炎新解方 原文網址 2020-07-15